Banco Bilbao Vizcaya Argentaria’s Acadia Pharmaceuticals ACAD Stock Holding History

Banco Bilbao Vizcaya Argentaria’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,000	Closed	-$242K	–	672
2020 Q2	$242K	Sell	5,000 -5,000	-50%	-$240K	0.01%	666
2020 Q1	$422K	Hold	10,000	–	–	0.02%	522
2019 Q4	$427K	Buy	+10,000	New	+$435K	0.01%	554

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Banco Bilbao Vizcaya Argentaria's ACAD Position: Q3 2020 in Review

Banco Bilbao Vizcaya Argentaria sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 5,000 shares — an estimated $242K sold.

Banco Bilbao Vizcaya Argentaria first reported a position in ACAD in Q4 2019 and held it in 3 quarters. The position peaked at $427K in Q4 2019. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

Banco Bilbao Vizcaya Argentaria reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Banco Bilbao Vizcaya Argentaria sold 5,000 Acadia Pharmaceuticals shares in Q3 2020, an estimated $242K.
Banco Bilbao Vizcaya Argentaria first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 3 quarters.
Banco Bilbao Vizcaya Argentaria's Acadia Pharmaceuticals position peaked at $427K in Q4 2019.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Banco Bilbao Vizcaya Argentaria's 13F filing for Q3 2020, filed 12 Nov 2020.